Clinical trial · no report yet · Phase 3
frontMIND
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- NCT04824092 ↗
- Active not recruiting
- Incyte Corporation
- 96 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 40 | |
| YouTube | 31 | |
| Podcasts | 23 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab; Lenalidomide; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; Tafasitamab placebo; Lenalidomide placebo
- Arms
- Tafasitamab plus lenalidomide in addition to R-CHOP · Experimental
- Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP · Placebo comparator
- Enrollment
- 899
- Primary outcomes
- PFS-INV
- Sponsor
- Incyte Corporation
- Start
- May 11, 2021
- Primary completion
- Sep 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04824092 · updated Apr 1, 2026
Publications
linked from the registry- Lenz G, Trneny M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, Duell J, Jeon YW, Cheah CY, Westin J, Ye JZ, Caguioa PB, Belada D, Shin HJ, Oh SY, Amorim S, Ku M, Mocikova H, Jimenez JL, Gaidano G, Rosenwald A, Chiarle R, Colucci P, Ioannidis S, Cheng L, Vitolo U; frontMIND Study Investigators. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026 Jun 20;407(10547):2528-2541. doi: 10.1016/S0140-6736(26)00866-4. Epub 2026 May 30. PubMed 42217458
- Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Poulsen CB, Gang AO, Brown P, El-Galaly TC, Stauffer Larsen T. International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma. Clin Lymphoma Myeloma Leuk. 2026 Jan;26(1):e62-e76. doi: 10.1016/j.clml.2025.08.020. Epub 2025 Sep 3. PubMed 40993016
- Duell J, Westin J. The future of immunotherapy for diffuse large B-cell lymphoma. Int J Cancer. 2025 Jan 15;156(2):251-261. doi: 10.1002/ijc.35156. Epub 2024 Sep 25. PubMed 39319495
- Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, Andre M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637. PubMed 37369099